Payment overview · 2025
General Payments
$417.64
21 reported records · 7 companies
Healthcare provider profile · identity verified
Charla J Evans, DO
Allopathic & Osteopathic Physicians|Family Medicine · MOBILE, AL · NPI 1770697500
Verified facts
What the public records show
CMS Open Payments records show Charla J Evans, DO received $417.64 in general payments during 2025 across 21 reported records.
Sumitomo Pharma America, Inc. accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 331 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $190.24 | 45.5% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.61 | 18.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.03 | 10.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.05 | 8.6% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $23.82 | 5.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.75 | 5.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.14 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.64 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $190.24 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $77.61 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.05 | 2 | 2025 |
Source payment records
|
|||||
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
331 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 931 | 275 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 590 | 88 |
| Gabapentin | Gabapentin | 512 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 396 | 129 |
| Lisinopril | Lisinopril | 373 | 112 |
| Alprazolam | Alprazolam | 339 | 48 |
| Ozempic | Semaglutide | 331 | 55 |
| Trazodone Hcl | Trazodone Hcl | 296 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 91 |
| Metformin Hcl | Metformin Hcl | 270 | 73 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 268 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 259 | 44 |
| Losartan Potassium | Losartan Potassium | 256 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 251 | 75 |
| Clonazepam | Clonazepam | 236 | 29 |
| Furosemide | Furosemide | 235 | 80 |
| Tizanidine Hcl | Tizanidine Hcl | 233 | 44 |
| Tramadol Hcl | Tramadol Hcl | 218 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 205 | 38 |
| Omeprazole | Omeprazole | 205 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 191 | 27 |
| Mounjaro | Tirzepatide | 184 | 34 |
| Potassium Chloride | Potassium Chloride | 175 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 172 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 29 |
| Meloxicam | Meloxicam | 149 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 42 |
| Carvedilol | Carvedilol | 137 | 42 |
| Famotidine | Famotidine | 135 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 37 |
| Celecoxib | Celecoxib | 124 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 28 |
| Ezetimibe | Ezetimibe | 123 | 43 |
| Montelukast Sodium | Montelukast Sodium | 120 | 35 |
| Estradiol | Estradiol | 111 | 30 |
| Spironolactone | Spironolactone | 104 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 102 | 28 |
| Bupropion Xl | Bupropion Hcl | 101 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 32 |
| Linzess | Linaclotide | 97 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 22 |
| Sertraline Hcl | Sertraline Hcl | 86 | 23 |
| Buspirone Hcl | Buspirone Hcl | 85 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 20 |
| Diazepam | Diazepam | 81 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 12 |
| Lorazepam | Lorazepam | 75 | 15 |
| Allopurinol | Allopurinol | 73 | 23 |
| Metformin Hcl Er | Metformin Hcl | 73 | 26 |
| Jardiance | Empagliflozin | 70 | 19 |
| Prednisone | Prednisone | 70 | 42 |
| Gemtesa | Vibegron | 68 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 14 |
| Trulicity | Dulaglutide | 67 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 20 |
| Promethazine Hcl | Promethazine Hcl | 61 | 16 |
| Fluconazole | Fluconazole | 60 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 47 |
| Eliquis | Apixaban | 58 | 13 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 56 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 55 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Topiramate | Topiramate | 54 | 11 |
| Vascepa | Icosapent Ethyl | 54 | 14 |
| Azithromycin | Azithromycin | 53 | 46 |
| Ibuprofen | Ibuprofen | 51 | 19 |
| Farxiga | Dapagliflozin Propanediol | 49 | 17 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 49 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 29 |
| Mirtazapine | Mirtazapine | 47 | 11 |
| Mupirocin | Mupirocin | 47 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 13 |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Ondansetron Odt | Ondansetron | 38 | 21 |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Telmisartan | Telmisartan | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 11 |
| Nystatin | Nystatin | 35 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 14 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 13 |
| Lidocaine | Lidocaine | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 12 |
| Desloratadine | Desloratadine | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 17 |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Ramipril | Ramipril | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $417.64 · 21 records | Sumitomo Pharma America, Inc. | AREXVY, Auvelity, Cologuard Collection Kit, GEMTESA, LOREEV XR, SHINGRIX, Wegovy, YONSA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error